Dominance of the α1B-adrenergic receptor and its subcellular localization in human and TRAMP prostate cancer cell lines

Journal of Receptors and Signal Transduction

Volumn 27, Issue 1, 2007, Pages 27-45

  Shi, Ting ^a   Gaivin, Robert J ^a   McCune, Dan F ^b   Gupta, Manveen ^a   Perez, Dianne M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WILKES UNIVERSITY   (United States)

Author keywords

Adrenergic receptor; DU145; Intracellular localization; PC3; Prostate cancer; TRAMP

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ANDROGEN; ENHANCED GREEN FLUORESCENT PROTEIN; 5 METHYLURAPIDIL; 5-METHYLURAPIDIL; ADRENALIN; ADRENERGIC RECEPTOR ALPHA(1B); ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; CANCER CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INCUBATION TIME; LIGAND BINDING; MOUSE; NONHUMAN; OXYGEN SATURATION; PROSTATE CANCER; PROTEIN LOCALIZATION; ANIMAL; DOSE RESPONSE; MALE; METABOLISM; PROSTATE TUMOR; PROTEIN BINDING; TUMOR CELL LINE;

ADRENERGIC AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EPINEPHRINE; HUMANS; MALE; MICE; PIPERAZINES; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 33847033761     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890601087487     Document Type: Article

References (35)

1. 1-Adrenergic receptors: New insights and directions. J Pharmacol Exp Ther 2001, 298, 403-410.
2. 1 adrenoceptor subtypes in human prostate. J Urol 1993, 150, 546-551.
3. 1-Adrenoceptor subtype in the human prostate. Br J Urol 1994, 74, 585-589.
4. 1a subtype. Mol Pharmacol 1994, 45, 703-708.
5. Wingo PA, Tong T-N, Bolden S, Cancer statistics. CA Cancer J Clin 1997, 47, 5-27.
6. Woolf SH. Screening for the prostate cancer with prostate-specific antigen. An examination of evidence. N Engl J Med 1995, 333, 1401-1405.
7. Isaacs JT. The role of androgens in prostatic cancer. Vitam Horm 1994, 49, 433-502.
8. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000, 14, 2410-2434.
9. 1A-adrenoceptor in the human prostate. J Urol 1995, 154, 2096-2099.
10. Kyprianou N, Litvak J, Alexander RB, Borkowski A, Jacobs SC. Induction of prostate apoptosis by doxazosin. J Urol 1998, 159, 1810-1815.
11. Kyprianou N, Lepor H, Wyllie MG. Prostatic adrenoceptors and uroselectivity. Prostate 1997, 3, 202-207
12. 1-Adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin N Am 1990, 17, 641-650.
13. 1a- adrenoceptor subtype in the rat, monkey, and human urinary bladder and prostate. J Urol 1997, 157, 1032-1038.
14. 1-Adrenoceptor antagonists, prazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patient with benign prostatic hyperplasia. J Urol 1999, 161, 2002-2007.
15. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997, 57, 3325-30.
16. 1b-adrenoceptor with green fluorescent protein. Mol Endocrinol 1998, 12, 1099-1111.
17. 1D-adrenergic receptors to multiple signaling pathways is both G-protein and cell-type specific. Mol Pharmacol 1993, 44, 784-795.
18. Gupta A, Devi LA. The use of receptor-specific antibodies to study G-protein-coupled receptors. Mt Sinai J Med 2006, 73, 673-681.
19. 1-adrenergic receptor subtypes. J Pharmacol Exp Ther 2002, 302, 58-65.
20. 1-adrenoceptor subtypes. Mol Pharmacol 2002, 61, 1008-1066.
21. 1B-Adrenergic receptor subcellular distribution and function. J Biol Chem 1995, 270, 8902-8909.
22. 1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. Life Sci 2002, 70, 2113-2224.
23. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, Kobilka BK. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 1997, 272, 2587-2590.
24. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993, 365, 649-51.
25. Perry SJ.; Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002, 12, 130-138.
26. 1D-adrenergic receptors through a PDZ domain-mediated interaction. J Biol Chem 2006, 281, 12414-12420.
27. 1- Adrenergic receptors activate Ca (2+)-permeable cationic channels in prostate cancer epithelial cells. J Clin Invest 2003, 111, 1691-1701.
28. 1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation. J Med Chem 2005, 48, 7750-7763.
29. 1-adrenergic receptor subtypes and signal transduction in SK-N-MC and NB41A3 neuronal cell lines. Mol Pharmacol 1993, 44, 76-86.
30. 1- adrenoceptors in DDT1 MF-2 and BC3 H-1 clonal cell lines. Eur J Pharmacol 1992, 226, 141-148.
31. 1-adrenergic receptor subtypes. Endocrinology 2004, 145, 5157-5167.
32. Price DT, Rudner X, Michelotti GA, Schwinn DA. Immortalization of a human prostate stromal cell line using a recombinant retroviral approach. J Urol 2000, 164, 2145-2150.
33. Xu K, Wang X, Ling M, Wong Y. Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines. Chin Med J (Engl) 2003, 116, 1673-1677.
34. 1-AR) antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease. Prostate Suppl 2000, 9, 42-46.
35. 1-adrenoceptor-independent action. Cancer Res 2002, 62, 597-602.